Editorial Policies

Aims and Scope

The most important goals of the journal are the aggregation, analysis and objective assessment of the most significant scientific and practice achievements in clinical medicine, publication of the most promising results of the interdisciplinary research by the Russian and foreign authors. The Almanac of Clinical Medicine highlights scientific, clinical and organizational aspects of a broad range of medical specialties, such as pediatrics, neurology, gastroenterology, endocrinology, dermatovenereology, oncology, urology, gynecology, minimally invasive surgery, transplantology, etc. Much attention is paid to the problems of postgraduate medical training in the public healthcare system.

The purpose of the journal is to promote the achievement of the Russian medicine in the territory of the Russian Federation and abroad by publishing original articles with the results of fundamental research aimed at investigation of general pathological processes, as well as the results of clinical and experimental studies, to improve diagnostics and treatment of patients, as well as to present clinical cases, state-of-the-art lectures and literature reviews.
Both national and international researchers and clinicians are welcome to submit their papers to the journal in either Russian or English languages.

 

Sections

INVITED ARTICLE

Editors
  • Олеся Парпара

ARTICLES

Editors
  • Олеся Парпара

GUIDELINES

Editors
  • Олеся Парпара

REVIEW ARTICLE

Editors
  • Олеся Парпара

POINT OF VIEW

Editors
  • Олеся Парпара

LECTURE

Editors
  • Олеся Парпара

CLINICAL CASES

Editors
  • Олеся Парпара

ERRATUM

Editors
  • Олеся Парпара

Special Section: COVID-19

Editors
  • Олеся Парпара
 

Peer Review Process

1. An Executive Editor of the journal is responsible for acceptance and preliminary review of a submitted manuscript. He/she determines if the manuscript complies with the journal’s profile and requirements to manuscript formatting. All submitted articles are subject to plagiarism control (anti-plagiarism program “AntiPlagiat”, Russia).

2. Manuscripts that have not passed through preliminary selection process are rejected. The author is informed on the decision made. An unfavorable conclusion is sent to an author by e-mail.

3. Manuscripts that have passed through preliminary selection are sent for review. Reviewers are appointed by the Executive Editor.

4. Reviewing is done by members of the journal’s editorial board, the journal's editorial council and external reviewers from leading experts in the field working in areas of research that correspond to main topic of a manuscript.

5. Timeframe of reviewing is 15 working days. It may be prolonged at a reviewer’s request, as well as if additional experts are necessary.

6. Manuscripts are sent to reviewers in a blinded manner, without giving author’s names and coordinates.

7. Whether any potential conflict of interest is present, a reviewer must declare that and deny paper evaluation.

8. Reviewers keep manuscripts strictly confidential and strictly follow an author’s right for nondisclosure of information and data contained in the manuscript before publication. Additional experts may be invited by a reviewer only under permission of the publisher, provided they also keep confidentiality.

9. A review should contain a qualified analysis of the manuscript, objective and well-reasoned assessment and a sound conclusion on publication. A review is done in a written form as a free text, with highlights of the issues listed in the instruction for reviewers developed by the publisher. Based on his/hers well-reasoned judgement, a reviewer prepares a conclusion on further handling of the manuscript. The following decisions are possible:

1) the manuscript is recommended for publication а) as currently submitted, b) with corrections deemed necessary by a reviewer;

2) the manuscript should be sent for an additional review to another specialist;

3) to reject the manuscript.

10. In isolated cases, in accordance with a reviewer’s recommendation, the Editor may send the manuscript for additional reviewing, including statistical and methodological one.

11. Author of a manuscript under consideration is given the possibility to read the text of a review, whereby neither name of a reviewer not his/hers contact information is shown.

12. Manuscripts that were not recommended by reviewers for publication are not accepted for another consideration and/or review. An unfavorable conclusion of reviewing is sent to an author by e-mail.

13. If a review contains recommendations to change and modify the manuscript, the Executive Editor sends the review to the author suggesting to take the recommendations into account while preparing a new version of the manuscript or to reject them, partially or fully, with sound arguments. The manuscript, modified and/or corrected by an author, is sent for a second review.

14. We politely request that the editor be notified in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 2 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.

15. Should unsolvable contradictions as per the manuscript arise between an author and a reviewer, the Editorial Board has the right to send the manuscript to another reviewer. In the case of a conflict, a manuscript may be sent for consideration to one of members of Editorial Board. In such cases, final decision is made by the Editor-in-Chief.

16. Availability of a positive review is not an adequate rationale for publication of a manuscript. Final decision on advisability of publication is made by the Editorial Board and, in conflicting cases, by the Editor-in-Chief.

17. Original reviews are kept in the editorial office for five years.

18. The journal’s editorial board is continuously assessing quality of reviews by means of a Russian version of Review Quality Instrument (Version 3.2): van Rooyen S., Black N., Godlee F. J Clin Epidemiol 1999; 52:625–9.

 

Publication Frequency

The journal publishes 8 regular issues per year.

Online First (publications online ahead-of-print)

We are pleased to offer electronic publication of accepted papers prior to print publication. All articles that are posted online before print publication first undergo the entire peer-review and assessment procedure. And, all articles posted in this Online First section are published later in the printed version of Almanac of Clinical Medicine, according to the regular print schedule. The date of online publication is now the definite publication date for each paper. The version of an article appearing in this Online First section is, therefore, considered the final version and is fully citable. Thus, we will not be publishing “updated” or “corrected” versions of articles. Any errors found subsequently after online publication may only be corrected by publishing errata. These papers can be cited using the unique DOI (Digital Object Identifier) number. The DOI is included in both the print and electronic versions.

Online First articles that have not yet been published in a print issue should be cited in this format:

Zakharov SG, Golenkov AK, Misyurin VA, Kataeva EV, Baryshnikova MA, Chuksina YuYu, Mitina TA, Trifonova EV, Vysotskaya LL, Chernykh YuB, Klinushkina EF, Belousov KA, Finashutina YuP, Misyurin AV. Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3, DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR). *Almanac of Clinical Medicine*. Published online December 14, 2018; doi: 10.18786/2072-0505-2018-46-8-734-741.

As soon as the print version of the article is available, the article appears in the online version of the new issue (the Latest Issue section) and disappears in the Online First section. After the paper has been published in print it should be cited as follows:

Zakharov SG, Golenkov AK, Misyurin VA, Kataeva EV, Baryshnikova MA, Chuksina YuYu, Mitina TA, Trifonova EV, Vysotskaya LL, Chernykh YuB, Klinushkina EF, Belousov KA, Finashutina YuP, Misyurin AV. Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3, DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR). *Almanac of Clinical Medicine*. 2018;46(8):734–41. doi: 10.18786/2072-0505-2018-46-8-734-741.

Online First articles are available in PDF format only.

NB! Since the articles in the Online First section are not assigned yet to a specific issue, bibliographic information, such as page ranges and issue numbers, are unknown. So that's why the articles can be cited only by way of their DOI!

 

Open Access Policy

"Almanac of Clinical Medicine"  is an open access journal. All articles are made freely available to readers immediatly upon publication.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.

For more information please read BOAI statement.

The Publisher grants usage rights to others using an open license (Creative Commons Attribution-NonCommercial 4.0 International) allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose.

 

Archiving

The journal uses the PKP Preservation Network (PKP PN) to digitally preserve all the published articles. The PKP PN is a part of LOCKSS (Lots of Copies Keep Stuff Safe) program offers decentralized and distributed preservation, seamless perpetual access, and preservation of the authentic original version of the content.

Also, the journal makes full-text archives on the Russian Science Electronic Library (http://elibrary.ru/) platform.

 

Indexation

Articles in "Almanac of Clinical Medicine" are indexed by several systems:

 

Publishing Ethics

The Ethic policy of "Almanac of Clinical Medicine" journal is based on recomendations from international commettees:

Reporting standarts

The Almanac of Clinical Medicine journal editorial team ask authors of reports of original research to present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.

Review and professional publication articles should also be accurate and objective, and editorial opinion works should be clearly identified as such.

Data Access and Retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Authorship clarified

The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before the work is submitted.

The Publisher does not prescribe the kinds of contributions that warrant authorship. It is recommended that authors adhere to the guidelines for authorship that are applicable in their specific research field. In absence of specific guidelines it is recommended to adhere to the following guidelines (based on ICMJE guidelines):

All authors whose names appear on the submission:

  1. made substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data; or the creation of new software used in the work AND
  2. drafted the work or revised it critically for important intellectual content AND
  3. approved the version to be published AND
  4. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Anyone who contributed to the research or manuscript preparation, but is not an author, should be acknowledged with their permission.

Submissions by anyone other than one of the authors will not be considered.

Research Ethics and Patient Consent (Statement of Human and Animal Rights)

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

Hazards for Human or Animal Subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

When reporting experiments on animals, authors have to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

Research involving human embryos, gametes, and stem cells

Manuscripts that report experiments involving the use of human embryos and gametes, human embryonic stem cells and related materials, and clinical applications of stem cells must include confirmation that all experiments were performed in accordance with relevant guidelines and regulations (See also Research involving human participants and/or animals)

The manuscript should include an ethics statement identifying the institutional and/or national research ethics committee (including the name of the ethics committee) approving the experiments and describing any relevant details. Authors should confirm that informed consent (See also Informed consent) was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Copies of approval and redacted consent documents may be requested by the Journal.

We encourage authors to follow the principles laid out in the 2016 ISSCR Guidelines for Stem Cell Research and Clinical Translation.

In deciding whether to publish papers describing modifications of the human germline, the Journal is guided by safety considerations, compliance with applicable regulations, as well as the status of the societal debate on the implications of such modifications for future generations. In case of concerns regarding a particular type of study the Journal may seek the advice from the Springer Nature Research Integrity Group.

The decision to publish a paper is the responsibility of the Editor-in-Chief of the Journal.

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Conflicts of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Conflicts include the following:

  • Financial — funding and other payments, goods and services received or expected by the authors relating to the subject of the work or from an organization with an interest in the outcome of the work;
  • Affiliations — being employed by, on the advisory board for, or a member of an organization with an interest in the outcome of the work;
  • Intellectual property — patents or trademarks owned by someone or their organization;
  • Personal — friends, family, relationships, and other close personal connections;
  • Ideology — beliefs or activism, for example, political or religious, relevant to the work;
  • Academic — competitors or someone whose work is critiqued.

For more information on conflicts of interest, see the guidance from the ICMJE and WAME.

Funding and Acknowledgement of Sources

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/  

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

Plagiarism

Plagiarism takes many forms, from passing off another paper as the author(s) own paper, to copying or paraphrasing substantial parts of another(s) paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Only original works are acceptable for publication in "Almanac of Clinical Medicine" journal. The journal does not allow any forms of plagiarism. Authors must not use the words, figures, or ideas of others without attribution. All sources must be cited at Almanac of Clinical Medicine journal take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. All the submitted articles are evaluated with plagiarism-checking software (Antiplagiat). Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgment, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to:

  • publishing an erratum or corrigendum (correction);
  • retracting the article;
  • taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies;
  • or taking appropriate legal action.

Also you can see ORI Avoiding Plagiarism, Self-plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing

Duplicate Submission and Redundant Publication

Almanac of Clinical Medicine journal consider only original content, i.e. articles that have not been previously published, including in a language other than English. Articles based on content previously made public only on a preprint server, institutional repository, or in a thesis will be considered.

Manuscripts submitted to Almanac of Clinical Medicine journal must not be submitted elsewhere while under consideration and must be withdrawn before being submitted elsewhere. Authors whose articles are found to have been simultaneously submitted elsewhere may incur sanctions.

If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they must cite the previous articles and indicate how their submitted manuscript differs from their previous work. Reuse of the authors’ own words outside the Methods should be attributed or quoted in the text. Reuse of the authors’ own figures or substantial amounts of wording may require permission from the copyright holder and the authors are responsible for obtaining this.

Almanac of Clinical Medicine journal will consider extended versions of articles published at conferences provided this is declared in the cover letter, the previous version is clearly cited and discussed, there is significant new content, and any necessary permissions are obtained.

Redundant publication, the inappropriate division of study outcomes into more than one article (also known as salami slicing), may result in rejection or a request to merge submitted manuscripts, and the correction of published articles. Duplicate publication of the same, or a very similar, article may result in the retraction of the later article and the authors may incur sanctions.

Citation Manipulation

Authors whose submitted manuscripts are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, may incur sanctions.

Editors and reviewers must not ask authors to include references merely to increase citations to their own or an associate’s work, to the journal, or to another journal they are associated with.

Fundamental errors in published works, Corrections and Retractions

When an author discovers a significant error or inaccuracy in his/her own published work, it is the authors obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper.

If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

When errors are identified in published articles, the publisher will consider what action is required and may consult the editors and the authors’ institution(s). 

Errors by the authors may be corrected by a corrigendum, and errors by the publisher — by an erratum (see more).

If there are errors that significantly affect the conclusions or there is evidence of misconduct, this may require retraction or an expression of concern following the COPE Retraction Guidelines. All authors will be asked to agree to the content of the appropriate notice.

Sanctions

If Almanac of Clinical Medicine journal becomes aware of breaches of our publication ethics policies, the following sanctions may be applied:

  • Rejection of the manuscript and any other manuscripts submitted by the author(s).
  • Not allowing submission for 1–3 years.
  • Prohibition from acting as an editor or reviewer.

Almanac of Clinical Medicine journal may apply additional sanctions for severe ethical violations.

 

Author fees

Publication in "Almanac of Clinical Medicine" is free of charge for all the authors.

The journal doesn't have any Arcticle processing charges.

The journal doesn't have any Article submission charges.

 

Disclosure and Conflict of Interest

Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

 

Plagiarism detection

"Almanac of Clinical Medicine" use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.

 

Preprint and postprint Policy

Prior to acceptance and publication in "Almanac of Clinical Medicine", authors may make their submissions available as preprints on personal or public websites.

As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in "Almanac of Clinical Medicine" we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.

Glossary (by SHERPA)

Preprint - In the context of Open Access, a preprint is a draft of an academic article or other publication before it has been submitted for peer-review or other quality assurance procedure as part of the publication process. Preprints cover initial and successive drafts of articles, working papers or draft conference papers.
 
Postprint - The final version of an academic article or other publication - after it has been peer-reviewed and revised into its final form by the author. As a general term this covers both the author's final version and the version as published, with formatting and copy-editing changes in place.

 

CrossMark

CrossMark is a multi-publisher initiative from Crossref, provides a standard way for readers to locate the authoritative version of an article or other published content. By applying the CrossMark logo, journal "Almanac of Clinical Medicine" is committing to maintaining the content it publishes and to alerting readers to changes if and when they occur.

Clicking the CrossMark logo on a document will tell you its current status and may also give you additional publication-record information about the document.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies